SK Bioscience joins $99m BDBV vaccine development project

What happened: SK Bioscience said it will join a Bundibugyo virus vaccine development project involving IAVI and Hilleman Laboratories, backed by BARDA funding. Key numbers: Up to $99 million from BARDA, with $36 million in initial funding. The project includes Phase 1 trials. Why it matters: IAVI's CEO said the BARDA funding reflects confidence in the vaccine candidate and the participating organizations' capabilities. SK Bioscience will lead process scale-up and commercial-scale manufacturing, with IDT Biologika handling aseptic filling.

SK Bioscience said it will join a Bundibugyo virus vaccine development project involving IAVI and Hilleman Laboratories, backed by BARDA funding.

IAVI's CEO said the BARDA funding reflects confidence in the vaccine candidate and the participating organizations' capabilities. SK Bioscience will lead process scale-up and commercial-scale manufacturing, with IDT Biologika handling aseptic filling.